Monte Rosa Therapeutics Ratios (2022-2025) | GLUE

Ratios Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin (Quarter) -2,996.71%-640.21%-258.12%107.22%56.17%-47.84%-236.98%-1,656.81%
EBIT Margin (Quarter) -3,284.49%-695.25%-287.84%130.90%51.85%-67.06%-258.26%-1,787.67%
EBITDA Margin (Quarter) -3,001.60%-645.09%-255.11%20.45%55.24%-53.20%-211.11%-1,679.79%
Operating Margin (Quarter) -3,284.49%-695.25%-287.84%130.90%51.85%-67.06%-258.26%-1,787.67%
Net Margin (Quarter) -3,006.11%-645.58%-258.89%103.65%55.20%-53.01%-212.10%-1,658.94%
FCF Margin (Quarter) -3,717.01%-634.48%-232.13%218.77%-55.43%-157.00%808.83%-1,699.93%
Efficiency
Assets Average (Quarter) 325.71M293.82M265.36M277.93M285.25M305.43M329.60M376.91M415.97M376.39M409.71M454.25M
Equity Average (Quarter) 257.57M228.69M199.09M181.89M165.88M188.59M215.06M214.20M249.05M271.62M256.96M239.45M
Invested Capital (Quarter) 271.41M243.73M213.65M184.52M179.25M152.52M224.67M205.46M222.94M275.16M268.08M245.84M233.06M
Asset Utilization Ratio (Quarter) 0.000.020.050.200.380.470.440.27
Leverage & Solvency
Equity Ratio (Quarter) 0.790.790.770.730.590.570.650.650.510.700.750.530.52
Valuation
Enterprise Value (Quarter) -264.83M-52.81M-47.03M-59.05M-128.10M-99.75M-108.85M-125.58M-224.25M-335.08M-300.86M-208.34M-129.88M
Return Ratios
Return on Sales (Quarter) -0.30%-0.06%-0.03%0.01%0.01%-0.01%-0.02%-0.17%
Return on Capital Employed (Quarter) -61.95%-59.03%-52.99%-44.79%-6.70%18.01%24.32%21.51%-13.90%
Return on Invested Capital (Quarter) -0.01%-0.01%-0.01%-0.01%0.00%0.00%0.00%0.00%0.00%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Return on Equity (Quarter) -0.01%-0.01%-0.01%-0.01%-0.01%0.00%0.00%0.00%0.00%0.00%